ARCH Venture Partners

Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.

Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027.

Develops fungal genome-derived therapeutics for organ transplant rejection

Builds quantum computers using lasers to hold individual atoms in place

Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD

Develops ultrasound-mediated nonviral genetic medicines

Develops next-generation RNAi therapeutics and engineering platform for multiple disease areas

Develops single-molecule PCR technology for genomics measurement

Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies

Decodes cellular networks to advance human health

Develops functional single-cell analysis tools and platforms for life science research

Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases

Builds technologies for spatial biology and multi-omics innovation

Develops medicines targeting historically undruggable protein targets in cancer